• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Dexcom launches Stelo over-the-counter CGM

Dexcom launches Stelo over-the-counter CGM

August 26, 2024 By Sean Whooley

Dexcom Stelo worn by pickleball player
A pickleball player wears the Stelo over-the-counter CGM. [Image courtesy of Dexcom]
Dexcom (Nasdaq: DXCM) today announced a significant product launch as another continuous glucose monitor (CGM) is hitting the market.

Our sister site, Drug Delivery Business News, reported today that Dexcom launched its Stelo over-the-counter (OTC) CGM biosensor.

The San Diego-based company designed Stelo, a small, wearable sensor, specifically for people with type 2 diabetes who do not use insulin. Stelo features a 15-day wear based on the G7 platform. It offers a software experience tailored specifically for non-insulin users.

Dexcom said Stelo makes it easier for the target population to access CGM and offers an option for those who don’t have insurance coverage for CGM.

Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Business/Financial News, Diabetes, Featured, Health Technology, Patient Monitoring Tagged With: Dexcom

More recent news

  • Siemens Healthineers exits general ultrasound to focus on cardiac imaging
  • Johnson & Johnson MedTech sets mid-2027 target for ortho spinoff, as Q3 device sales disappoint
  • Olympus receives FDA warning letter after international inspections
  • Stryker dives into soft-tissue robotics with $400M play for CMR Surgical’s Versius
  • Massachusetts Life Sciences Center offers grants to lower medtech commercial risk

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy